The effect of drug eluting stents on cardiovascular events in patients with intermediate lesions and borderline fractional flow reserve

Catheterization and Cardiovascular Interventions

Volumn 70, Issue 4, 2007, Pages 525-531

  Lavi, Shahar ^a   Rihal, Charanjit S ^a   Yang, Eric H ^a   Fassa, Amir Ali ^a   Elesber, Ahmad ^a   Lennon, Ryan J ^a   Mathew, Verghese ^a   David Jr , Holmes R ^a   Lerman, Amir ^a  

^a MAYO CLINIC   (United States)

Author keywords

Fractional flow reserve; Outcome; Stents

Indexed keywords

ADULT; AGED; ANGIOGRAPHY; ARTICLE; CARDIOVASCULAR SYSTEM; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG ELUTING STENT; FEMALE; HEART EJECTION FRACTION; HEART INFARCTION; HEART INJURY; HEART MUSCLE REVASCULARIZATION; HUMAN; KAPLAN MEIER METHOD; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; SURVIVAL RATE;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CARDIOVASCULAR DISEASES; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; DRUG-ELUTING STENTS; FEMALE; FOLLOW-UP STUDIES; FRACTIONAL FLOW RESERVE, MYOCARDIAL; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; METALS; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROSTHESIS DESIGN; RESEARCH DESIGN; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX; STENTS; TIME FACTORS; TREATMENT OUTCOME;

EID: 35349011174     PISSN: 15221946     EISSN: 1522726X     Source Type: Journal    
DOI: 10.1002/ccd.21154     Document Type: Article

References (34)

1. Pijls NHJ, Van Gelder B, Van der Voort P, Peels K, Bracke FALE, Bonnier HJRM, El Gamal MIH. Fractional flow reserve: A useful index to evaluate the influence of an epicardial coronary stenosis on myocardial blood flow. Circulation 1995;92:3183-3193.
2. Pijls N, van Son J, Kirkeeide R, De Bruyne B, Gould K. Experimental basis of determining maximum coronary, myocardial, and collateral blood flow by pressure measurements for assessing functional stenosis severity before and after percutaneous transluminal coronary angioplasty. Circulation 1993;87:1354-1367.
3. Pijls NHJ, de Bruyne B, Peels K, van der Voort PH, Bonnier HJRM, Bartunek J, Koolen JJ. Measurement of fractional flow reserve to assess the functional severity of coronary-artery stenoses. N Engl J Med 1996;334:1703-1708.
4. Kern MJ, Lerman A, Bech J-W, De Bruyne B, Eeckhout E, Fearon WF, Higano ST, Lim MJ, Meuwissen M, Piek JJ, et al. Physiological assessment of coronary artery disease in the cardiac catheterization laboratory. A scientific statement from the American heart association committee on diagnostic and interventional cardiac catheterization, council on clinical cardiology. Circulation 2006;114:1321-1341.
5. Bech GJW, De Bruyne B, Pijls NHJ, de Muinck ED, Hoorntje JCA, Escaned J, Stella PR, Boersma E, Bartunek J, Koolen JJ, et al. Fractional flow reserve to determine the appropriateness of angioplasty in moderate coronary stenosis: A randomized trial. Circulation 2001;103:2928-2934.
6. Berger A, Botman K-J, MacCarthy PA, Wijns W, Bartunek J, Heyndrickx GR, Pijls NHJ, De Bruyne B. Long-term clinical outcome after fractional flow reserve-guided percutaneous coronary intervention in patients with multivessel disease. J Am Coll Cardiol 2005;46:438-442.
7. Klauss V, Erdin P, Rieber J, Leibig M, Stempfle H-U, Konig A, Baylacher M, Theisen K, Haufe MC, Sroczynski G, et al. Fractional flow reserve for the prediction of cardiac events after coronary stent implantation: Results of a multivariate analysis. Heart 2005;91:203-206.
8. Pijls NHJ, Klauss V, Sieben U, Powers E, Takazawa K, Fearon WF, Escaned J, Tsurumi Y, Akasaka T, Samady H, et al. Coronary pressure measurement after stenting predicts adverse events at follow-up: A multicenter registry. Circulation 2002;105:2950-2954.
9. Bech MD GJW, De Bruyne MDP, Bernard, Bonnier MDP, Hans JRM, Bartunek MDJ, Wijns MDP, William, Peels MD K. Long-term follow-up after deferral of percutaneous transluminal coronary angioplasty of intermediate stenosis on the basis of coronary pressure measurement. J Am Coll Cardiol 1998;31:841-847.
10. Rieber J, Schiele TM, Koenig A, Erhard I, Segmiller T, Stempfle H-U, Theisen K, Jung P, Siebert U, Klauss V. Long-term safety of therapy stratification in patients with intermediate coronary lesions based on intracoronary pressure measurements. Am J Cardiol 2002;90:1160-1164.
11. Authors/Task Force Members, Silber S, Albertsson P, Aviles FF, Camici PG, Colombo A, Hamm C, Jorgensen E, Marco J, Nordrehaug J-E, et al. Guidelines for percutaneous coronary interventions: the task force for percutaneous coronary interventions of the european society of cardiology. Eur Heart J 2005;26:804-847.
12. Legalery P, Schiele F, Seronde M-F, Meneveau N, Wei H, Didier K, Blonde M-C, Caulfield F, Bassand J-P. One-year outcome of patients submitted to routine fractional flow reserve assessment to determine the need for angioplasty. Eur Heart J 2005;26:2623-2629.
13. Bech GJW, Pijls NHJ, De Bruyne B, Peels KH, Michels HR, Bonnier HJRM, Koolen JJ. Usefulness of fractional flow reserve to predict clinical outcome after balloon angioplasty. Circulation 1999;99:883-888.
14. Holmes DR Jr, Leon MB, Moses JW, Popma JJ, Cutlip D, Fitzgerald PJ, Brown C, Fischell T, Wong SC, Midei M, et al. Analysis of 1-year clinical outcomes in the sirius trial: A randomized trial of a sirolimus-eluting stent versus a standard stent in patients at high risk for coronary restenosis. Circulation 2004;109:634-640.
15. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, Turco M, Caputo R, Bergin P, Greenberg J, et al. One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS Stent: The TAXUS-IV trial. Circulation 2004;109:1942-1947.
16. Lemos PA, Serruys PW, van Domburg RT, Saia F, Arampatzis CA, Hoye A, Degertekin M, Tanabe K, Daemen J, Liu TKK, et al. Unrestricted utilization of sirolimus-eluting stents compared with conventional bare stent implantation in the "real world": The rapamycin-eluting stent evaluated at Rotterdam Cardiology Hospital (RESEARCH) Registry. Circulation 2004;109:190-195.
17. Roiron C, Sanchez P, Bouzamondo A, Lechat P, Montalescot G. Drug-eluting stents: A meta-analysis of randomised controlled trials. Heart 2006;92:641-649.
18. Pfisterer M, Brunner-La Rocca HP, Buser PT, Rickenbacher P, Hunziker P, Mueller C, Jeger R, Bader F, Osswald S, Kaiser C. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: An observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol 2006;48:2584-2591.
19. Moses JW, Stone GW, Nikolsky E, Mintz GS, Dangas G, Grube E, Ellis SG, Lansky AJ, Weisz G, Fahy M. Drug-eluting stents in the treatment of intermediate lesions: Pooled analysis from four randomized trials. J Am Coll Cardiol 2006;47:2164-2171.
20. De Bruyne B, Bartunek J, Sys SU, Heyndrickx GR. Relation between myocardial fractional flow reserve calculated from coronary pressure measurements and exercise-induced myocardial ischemia. Circulation 1995;92:39-46.
21. Murtagh B, Higano S, Lennon R, Mathew V, Holmes J, David R, Lerman A. Role of incremental doses of intracoronary adenosine for fractional flow reserve assessment. Am Heart J 2003;146:99-105.
22. Antman E, Bassand J-P, Klein W, Ohman M, Lopez Sendon JL, Ryden L, Simoons M, Tendera M. Myocardial infarction redefined - A consensus document of The Joint European Society of Cardiology/American College of Cardiology committee for the redefinition of myocardial infarction: The Joint European Society of Cardiology/American College of Cardiology Committee. J Am Coll Cardiol 2000;36:959-969.
23. Wongpraparut N, Yalamanchili V, Pasnoori V, Satran A, Chandra M, Masden R, Leesar MA. Thirty-month outcome after fractional flow reserve-guided versus conventional multivessel percutaneous coronary intervention. Am J Cardiol 2005;96:877-884.
24. Lopez-Palop R, Pinar E, Lozano I, Saura D, Pico F, Valdes M. Utility of the fractional flow reserve in the evaluation of angiographically moderate in-stent restenosis. Eur Heart J 2004;25:2040-2047.
25. Pijls NHJ. Is it time to measure fractional flow reserve in all patients? J Am Coll Cardiol 2003;41:1122-1124.
26. Mates M, Hrabos V, Hajek P, Rataj O, Vojacek J. Long-term follow-up after deferral of coronary intervention based on myocardial fractional flow reserve measurement. Coronary Artery Dis 2005;16:169-174.
27. Cutlip DE, Chhabra AG, Baim DS, Chauhan MS, Marulkar S, Massaro J, Bakhai A, Cohen DJ, Kuntz RE, Ho KKL. Beyond restenosis: Five-year clinical outcomes from second-generation coronary stent trials. Circulation 2004;110:1226-1230.
28. Katritsis DG, Ioannidis JPA. Percutaneous coronary intervention versus conservative therapy in nonacute coronary artery disease: A meta-analysis. Circulation 2005;111:2906-2912.
29. Oberhoff M, Karsch KR. Who wants his plaque sealed? Eur Heart J 2003;24:494-495.
30. Eisenberg MJ. Drug-eluting stents: The price is not right. Circulation 2006;114:1745-1754.
31. Bucher HC, Hengstler P, Schindler C, Guyatt GH. Percutaneous transluminal coronary angioplasty versus medical treatment for non-acute coronary heart disease: Meta-analysis of randomised controlled trials. BMJ 2000;321:73-77.
32. Henderson RA, Pocock SJ, Clayton TC, Knight R, Fox KAA, Julian DG, Chamberlain DA. Seven-year outcome in the RITA-2 trial: Coronary angioplasty versus medical therapy. J Am Coll Cardiol 2003;42:1161-1170.
33. Glaser R, Selzer F, Faxon DP, Laskey WK, Cohen HA, Slater J, Detre KM, Wilensky RL. Clinical progression of incidental, asymptomatic lesions discovered during culprit vessel coronary intervention. Circulation 2005;111:143-149.
34. Shuchman M. Debating the risks of drug-eluting stents. N Engl J Med 2007;356:325-328.